Questions? Feedback? powered by Olark live chat software

Oncoproteins

Oncoproteins are proteins encoded by oncogenes which are involved in the regulation or synthesis of proteins linked to cancer tumor cell growth. Current oncoprotein research focuses on antibodies that can directly target the oncoproteins inside cancer cells and suppress aggressive cancer growth. This type of antibody therapy has proven better specificity over standard chemotherapy techniques. Typical cells will eventually die by pre-programmed cell death, or apoptosis. This process occurs when the cell is not functioning properly or is aged and ready to be replaced by a fresh substitute. Cancer cells do not respond to apoptosis signals and instead proliferate rapidly. Cancer can also occur when the typical cell- cycle functions get out of control. There are many different oncogenes encoding for several oncoproteins. These include growth factors, receptor tyrosine kinases, cytoplasmic regulatory subunits, transcription factors, and regulatory GTPases. One example includes SH domains. Src homology domains (pronounced SARC as in sarcoma) are portions of small binding proteins found in Src oncoproteins. Src is an enzyme encoded by the SRC gene. SRC is a cancer gene that contains the code for a tyrosine kinase that plays an important role in the formation of sarcomas and other cancers when the normal cellular signals fail to function. Mutations in normal genetic material can cause genes to be expressed as oncoproteins. Many tumor suppressor genes also exist that protect a cell from cancer. These tumor suppressors usually interact with one step in the process of cancer production.

The CMA2 protein is involved in white blood cell antigens, tumor biomarkers, and serum proteins. The anti-CMA2 antigen binds against the CMA2 affecting its ability to present peptide antigens to the immune system. Defects in CMA2 cause hypercatabolic hypoproteinemia. Hypercatabolic hypoproteinemia is a disorder of the endogenous catabolism of albumin and immunoglobulin. This disorder is characterized by gastrointestinal disorders in which affected individuals may suffer from intestinal inflammation, small bowel protein loss, and congestive heart failure. The anti-KLK5 antibody is also known as the anti-Kallikrein 5 antibody. This antibody binds against the kallikrein 5 target which is expressed in skin, breast tissue, testis tissue, and the brain. It is thought to be involved in desquamation. Desquamation occurs naturally in skin tissues however, it can also be pathogenic. This is characterized by thick layers of skin peeling off and leaving a dry, scaly appearance.

 
Product Number Title Applications Host Clonality
AC16-0045 Anti-KLF4 Antibody ELISA, WB Rabbit Polyclonal
AC16-0055 Anti-VEGF Receptor 1 Antibody ELISA, WB, IHC(P), IP Rabbit Polyclonal
AC16-0045-01 Anti-KLF4 Antibody (AMCA) ELISA, WB Rabbit Polyclonal
AC16-0045-02 Anti-KLF4 Antibody (AP) ELISA, WB Rabbit Polyclonal
AC16-0045-03 Anti-KLF4 Antibody (APC) ELISA, WB Rabbit Polyclonal
AC16-0045-04 Anti-KLF4 Antibody (APC-Cy5.5) ELISA, WB Rabbit Polyclonal
AC16-0045-05 Anti-KLF4 Antibody (APC-Cy7) ELISA, WB Rabbit Polyclonal
AC16-0045-06 Anti-KLF4 Antibody (Avidin) ELISA, WB Rabbit Polyclonal
AC16-0045-07 Anti-KLF4 Antibody (Biotin) ELISA, WB Rabbit Polyclonal
AC16-0045-08 Anti-KLF4 Antibody (BPE) ELISA, WB Rabbit Polyclonal
AC16-0045-09 Anti-KLF4 Antibody (Cy3) ELISA, WB Rabbit Polyclonal
AC16-0045-10 Anti-KLF4 Antibody (Cy5) ELISA, WB Rabbit Polyclonal